Liquid Biopsy and Early Cancer Detection: Promise and Limitations
Liquid biopsy is transforming cancer detection through minimally invasive genomic testing, offering new opportunities for earlier diagnosis and monitoring.
Polygenic Risk Scores and the Genomic Data Gap: Promise, Limitations, and Equity in Precision Medicine
Polygenic risk scores may transform disease prediction, but gaps in genomic diversity continue to limit equity, accuracy, and access in precision medicine across global populations.
Artificial Intelligence in Precision Medicine
Artificial intelligence is reshaping precision medicine by improving diagnostics, predicting treatment response, and enabling more personalized, data-driven healthcare strategies.
Precision Medicine in Oncology Isn’t the Future - It’s Already Late
by: Shraddha HakaniPublished on: 17/05/2026Precision medicine in oncology is no longer a distant vision- it is a critical necessity. As cancer care evolves, biomarker-driven diagnostics, genomic sequencing, digital pathology, and AI-powered insights are transforming how clinicians detect.
A multidisciplinary community committed to advancing research, education, and clinical standards in precision medicine.
FOLLOW US
LEARN ABOUT THE
ABOPM
CUSTOMER CARE
LEGAL
Copyright 2026. American Board of Precision Medicine. All Rights Reserved.